림프종연구회 CISL33 임상시험 연구자모임 : 2023-02-25
교육일자 : 2023-02-25
교육장소 : 세종대학교 광개토관  
교육주제 : CISL33 임상시험 연구자모임 
주최기관 : 대한혈액학회
시행기관(지부/과) : 림프종연구회  
담당자 : 김혜진
연락처 : 02-516-6581  
이메일 : hematology@kams.or.kr      
교육종류 : 내과      
참석예상인원 : 80명
희망평점 : 3점  
지역 : 서울특별시
교육시간 : 3 시간 45분  
세부수강료 : 0원      
비고       

구분 월일 강의실 시간 교육제목  강사명(소속) 필수과목
교육시간 02-25 광계토관 13:10~13:25 A randomized phase II trial comparing rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) with RB as induction therapy in elderly patients with newly diagnosed and transplant-ineligible mantle cell lymphoma  임호영(전북대학교병원) 
교육시간 02-25 광계토관 13:25~13:40 A Phase II Study of Epigenetic Priming Using Azacitidine Followed by R-GDP Immunochemotherapy in Patients with Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma  홍준식(서울대학교병원) 
교육시간 02-25 광계토관 13:40~13:55 Multicenter Prospective Cohort Study of Hodgkin Lymphoma  엄현석(국립암센터) 
교육시간 02-25 광계토관 13:55~14:10 Phase II study of lenalidomide-R-CHOP for patients with diffuse large B cell lymphoma who are at high risk of central nervous system relapse  조형우(서울아산병원) 
교육시간 02-25 광계토관 14:10~14:25 Multicenter, open label, phase I/II study of azacitidine-CHOP for patients with nodal T-cell lymphoma with T-follicular helper phenotype  김석진(삼성서울병원) 
교육시간 02-25 광계토관 14:30~14:50 Selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with secondary central nervous system involving relapsed or refractory B-cell non-Hodgkin lymphoma  송가영(화순전남대학교병원) 
교육시간 02-25 광계토관 15:10~15:30 phase I/II study of the combination of venetoclax, rituximab and lenalidomide for relapsed or refractory primary central nervous system lymphoma  조형우(서울아산병원) 
교육시간 02-25 광계토관 14:50~15:10 Retrospective analysis of Infectious events in Lymphoma patients who were treated with bendamustine plus anti-CD20 monoclonal antibody  이준호(중앙대학교병원) 
교육시간 02-25 광계토관 15:30~15:50 Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphoma  윤상은(삼성서울병원) 
교육시간 02-25 광계토관 15:50~16:10 Phase II study of Concurrent Tislelizumab and Radiotherapy for treatment-na?ve, newly diagnosed lowꠓrisk extranodal NK/T-cell lymphoma, nasal type  윤상은(삼성서울병원) 
교육시간 02-25 광계토관 16:10~16:30 Duodenal-type Follicular Lymphoma in Korean population: A Multicenter Study  정종헌(국립암센터) 
교육시간 02-25 광계토관 16:30~17:00 The Antengene Pipeline Includes Multiple Novel Immuno-oncology and Targeted Ass  이동열(안텐진제약)